SEARCH

SEARCH BY CITATION

References

  • 1
    Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002; 8: 24450.
  • 2
    Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn’s disease. Gastroenterology 1993; 105: 171623.
  • 3
    Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54: 23741.
  • 4
    Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn’s disease patients. Scand J Gastroenterol 1995; 30: 699706.
  • 5
    Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn’s disease: economic and clinical potential of infliximab. Clin Ther 1998; 20: 100928.
  • 6
    Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004; 53: 14718.
  • 7
    Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol 1997; 32: 11349.
  • 8
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000; 342: 162732.
  • 9
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 10
    Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 2007; 132: 5265.
  • 11
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med 2007; 357: 23950.
  • 12
    Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53(Suppl 5.): V116.
  • 13
    Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index: National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 14
    Harvey R, Bradshaw J. A simple index for Crohn’s disease activity. Lancet 1980; 1: 514.
  • 15
    National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Crohn’s Disease. London: Technology Appraisal Guidance 40, April 2002.
  • 16
    Travis S, Trange E, Lemann A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55(Suppl. 1): i1635.
  • 17
    Rutgeerts P, Diamond R, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006; 63: 43342.
  • 18
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 40213.
  • 19
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004; 350: 87685.
  • 20
    Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. Am J Gastroenterol 2003; 98: 22328.
    Direct Link:
  • 21
    Lichtenstein G, Yan S, Bala M, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries and procedures in fistulizing Crohn’s disease. Gastroenterology 2005; 128: 8629.
  • 22
    Lichtenstein G, Yan S, Bala M, et al. Remission in patients with Crohn’s disease is associated with improvement in employment and quality of life and a decrease in hospitalisations and surgery. Am J Gastroneterol 2004; 99: 916.
    Direct Link:
  • 23
    Jewell DP, Satsangi J, Lobo A, et al. Infliximab use in Crohn’s disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol 2005; 17: 104752.
  • 24
    Jess T, Loftus E, Scott Harmsen W, et al. Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004. Gut 2006; 55: 124854.
  • 25
    Lichtenstein G, Feagan B, Cohen R, et al. Serious infections and mortality in association with therapies for Crohn’s Disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 62130.
  • 26
    Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997; 337: 102935.
  • 27
    Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999; 340: 1398405.
  • 28
    Marchal L, D’Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn’s disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19: 74954.
  • 29
    Wolters FL, Russel MG, Sijbrandij J, et al. Phenotype at diagnosis predicts recurrence rates in Crohn’s disease. Gut 2006; 55: 112430.
  • 30
    National Institute of Health and Clinical Excellence (NICE). Guidance on the Use of Infliximab for Psoriasis. London: Technology Appraisal Guidance 134, January 2008.
  • 31
    Department of Health. NHS Reference Costs 2005–06. Published 7 December 2006. Available at http://www.dh.gov.uk/en/publicationsandstatistics/publications/PublicationsPolicyAndGuidance/DH_062884.
  • 32
    Schering-Plough Ltd. UK Advisory Panel on Resource Use for CD Patients in Individual Post-Surgery Health States. Data on File. Available on request: Schering-Plough Ltd, 2007.
  • 33
    Casellas F, Arenas J, Baudet J. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm Bowel Dis 2005; 11: 48896.
  • 34
    Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095108.
  • 35
    NICE. Guide to the Methods of Technology Appraisal. National Institute of Health and Clinical Excellence, April 2004:26.
  • 36
    Kaplan GG, Hur C, Korzenik J, Sands BE. Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn’s disease: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:150920.
  • 37
    Jaisson-Hot I, Flourié B, Descos L, Colin C. Management for severe Crohn’s disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care 2004; 20: 2749.
  • 38
    Clark W, Raftery J, Song F, et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol Assess 2003; 7: 167.
  • 39
    Arseneau KO, Cohn SM, Cominelli F, Connors AF. Cost-utility of initial medical management for Crohn’s disease perianal fistulae. Gastroenterology 2001; 120: 164056.
  • 40
    Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 4957.
  • 41
    Casellas F, Rodrigo L, Niño P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn’s disease patients treated with infliximab and azathioprine for 4 years. Inflamm Bowel Dis 2007; 13: 1395400.
  • 42
    Rudolph SJ, Weinberg DI, McCabe RP. Long-term durability of Crohn’s disease treatment with infliximab. Dig Dis Sci 2008; 53: 103341.
  • 43
    Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007; 13: 523844.
  • 44
    Gregor JC, McDonald JWD, Klar N, et al. An evaluation of utility measurement in Crohn’s disease. Inflamm Bowel Dis 1997; 3: 26576.
  • 45
    Saro C, Da La Coba C, Casado MA, et al. Resource use in patients with Crohn’s disease treated with infliximab. Aliment Pharmacol Ther 2007; 10: 131323.
  • 46
    Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn’s disease. J Clin Gastroenterol 2002; 35: 1516.
  • 47
    Woehl A, Hawthorne B, Morgan C, Punekar Y, McEwan P. The epidemiology and healthcare resource use in patients with Crohn’s disease: a population based UK study. Value Health 2007; 10: A355.
  • 48
    Somerville M, Brooksby A, Scott DG. Maximizing the use of scarce resources: vial optimization. Rheumatology (Oxford) 2006; 45: 3534.
  • 49
    Towse A. What is NICE’s threshold? An external view. In: DevlinN, TowseA, eds. Cost Effectiveness Threshold: Economic and Ethical Issues. London: King’s Fund/Office of Health Economics, 2002.
  • 50
    D’Haens G, Baert F, Assche GV, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 2008; 371: 6607.
  • 51
    Sandborn W, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn’s disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 82938.
  • 52
    Makowiec F, Jehle EC, Starlinger M. Clinical course of perianal fistulas in Crohn’s disease. Gut 1995; 37: 696701.